Susan Altschuller | Alexion Pharmaceuticals, Inc. |
Ludwig N. Hantson | Alexion Pharmaceuticals, Inc. |
Paul J. Clancy | Alexion Pharmaceuticals, Inc. |
John J. Orloff | Alexion Pharmaceuticals, Inc. |
Brian Goff | Alexion Pharmaceuticals, Inc. |
Geoffrey C. Porges | Leerink Partners LLC |
Eric Schmidt | Cowen and Company |
Christopher J. Raymond | Piper Jaffray & Co. |
Matthew K. Harrison | Morgan Stanley & Co. LLC |
Anupam Rama | JPMorgan Securities LLC |
Terence Flynn | Goldman Sachs & Co. LLC |
Josh Schimmer | Evercore ISI |
Geoffrey Meacham | Barclays Capital, Inc. |
Robyn Karnauskas | Citigroup Global Markets, Inc. |
Ying Huang | Bank of America Merrill Lynch |
Martin Auster | Credit Suisse Securities (NYSE:USA) LLC |
Slanix Alex | RBC Capital Markets LLC |
Good morning, and welcome to the Alexion Pharmaceuticals First Quarter 2018 Results Call. Today's call is being recorded.
For opening remarks and introductions, I would now like to turn the call over to Ms. Susan Altschuller, Vice President, Investor Relations. Please go ahead, ma'am.